Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)

February 20, 2025 9:05 AM EST Send to a Friend
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $90.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login